Drug Profile
Brexanolone - Lipocine
Alternative Names: LPCN-1154Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Lipocine
- Class Antidepressants; Antiepileptic drugs; Small molecules; Steroids
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Postnatal depression
Highest Development Phases
- Phase II Postnatal depression
Most Recent Events
- 25 Mar 2024 Lipocine plans to file a New Drug Application (NDA) for postnatal depression by the end of the fourth quarter of 2024
- 25 Mar 2024 Lipocine completes enrolment in the pivotal pharmacokinetics trial for Postnatal depression in Unknown location (PO) before March 2024
- 25 Mar 2024 Lipocine initiates pivotal pharmacokinetics trial in Postnatal depression in Unknown location (PO) before March 2024